GZD2202, a novel TrkB inhibitor, suppresses BDNF-mediated proliferation and metastasis in neuroblastoma models

References

• Bagatell R, Cohn SL. Genetic discoveries and treatment advances in neuroblastoma. Curr Opin Pediatr. 2016;28:19–25.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Maris JM, Schleiermacher G, et al. Neuroblastoma. Nat Rev Dis Primers. 2016;2:16078.
   PubMed Web of Science ®Google Scholar
• Cao Y, Jin Y, Yu J, et al. Research progress of neuroblastoma related gene variations. Oncotarget. 2017;8:18444–18455.
   PubMedGoogle Scholar
• Brodeur GM, Minturn JE, Ho R, et al. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res. 2009;15:3244–3250.
   PubMed Web of Science ®Google Scholar
• Lange AM, Lo HW. Inhibiting Trk proteins in clinical cancer therapy. Cancers (Basel) 2018;10:E105.
   PubMed Web of Science ®Google Scholar
• Arévalo JC, Wu SH. Neurotrophin signaling: many exciting surprises!. Cell Mol Life Sci. 2006;63:1523–1537.
   PubMed Web of Science ®Google Scholar
• Schramm A, Schulte JH, Astrahantseff K, et al. Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer Lett. 2005;228:143–153.
   PubMed Web of Science ®Google Scholar
• Iyer R, Wehrmann L, Golden RL, et al. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. Cancer Lett. 2016;372:179–186.
   PubMed Web of Science ®Google Scholar
• Aveic S, Pantile M, Seydel A, et al. Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells. Oncotarget. 2016;7:5646–5663.
   PubMedGoogle Scholar
• Zage PE, Graham TC, Zeng L, et al. The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan. Cancer. 2011;117:1321–1391.
   PubMed Web of Science ®Google Scholar
• Drilon A, Siena S, Ou SI, et al. Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor Entrectinib: combined results from two Phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7:400–409.
   PubMed Web of Science ®Google Scholar
• Menichincheri M, Ardini E, Magnaghi P, et al. Discovery of Entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and Pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor. J Med Chem. 2016;59:3392–3408.
   PubMed Web of Science ®Google Scholar
• Ardini E, Menichincheri M, Banfi P, et al. Entrectinib, a Pan-Trk, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. Mol Cancer Ther. 2016;15:628–639.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Davis LE, Vaishnavi A, et al. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov. 2015;5:1049–1057.
   PubMed Web of Science ®Google Scholar
• Khotskaya YB, Holla VR, Farago AF, et al. Targeting Trk family proteins in cancer. Pharmacol Ther. 2017;173:58–66.
   PubMed Web of Science ®Google Scholar
• Azogu I, Plamondon H. Inhibition of TrkB at the nucleus accumbens, using ANA-12, regulates basal and stress-induced orexin A expression within the mesolimbic system and affects anxiety, sociability and motivation. Neuropharmacology. 2017;125:129–145.
   PubMed Web of Science ®Google Scholar
• Skerratt SE, Andrews M, Bagal SK, et al. The discovery of a potent, selective, and peripherally restricted Pan-Trk inhibitor (pf-06273340) for the treatment of pain. J Med Chem. 2016;59:10084–10099.
   PubMed Web of Science ®Google Scholar
• Albaugh P, Fan Y, Mi Y, et al. Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models. ACS Med Chem Lett. 2012;3:140–145.
   PubMed Web of Science ®Google Scholar
• Wang Z, Bian H, Bartual SG, et al. Structure-based design of tetrahydroisoquinoline-7-carboxamides as selective discoidin domain receptor 1 (DDR1) inhibitors. J Med Chem. 2016;59:5911–5916.
   PubMed Web of Science ®Google Scholar
• Bennett DL. Neurotrophic factors: important regulators of nociceptive function. Neuroscientist. 2001;7:13–17.
   PubMed Web of Science ®Google Scholar
• Aloe L. Rita Levi-Montalcini: the discovery of nerve growth factor and modern neurobiology. Trends Cell Biol. 2004;14:395–399.
   PubMed Web of Science ®Google Scholar
• Aloe L, Rocco ML, Bianchi P, et al. Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med. 2012;10:239.
   PubMed Web of Science ®Google Scholar
• Bannwarth B, Kostine M. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists? Drugs. 2014;74:619–626.
   PubMed Web of Science ®Google Scholar
• Kupferman ME1, Jiffar T, El-Naggar A, et al. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene. 2010;29:2047–2059.
   PubMed Web of Science ®Google Scholar
• Bao W, Qiu H, Yang T, et al. Upregulation of TrkB promotes epithelial-mesenchymal transition and anoikis resistance in endometrial carcinoma. PLoS One. 2013;8:e70616.
   PubMed Web of Science ®Google Scholar
• Nguyen N, Lee SB, Lee YS, et al. Neuroprotection by NGF and BDNF against neurotoxin-exerted apoptotic death in neural stem cells are mediated through Trk receptors, activating PI3-kinase and MAPK pathways. Neurochem Res. 2009;34:942–951.
   PubMed Web of Science ®Google Scholar
• Bernard-Gauthier V, Bailey JJ, Mossine AV, et al. A Kinome-wide selective radiolabeled TrkB/C inhibitor for in vitro and in vivo neuroimaging: synthesis, preclinical evaluation, and first-in-human. J Med Chem. 2017;60:6897–6910.
   PubMed Web of Science ®Google Scholar
• Bernard-Gauthier V, Mossine AV, Mahringer A, et al. Identification of [18F]TRACK, a fluorine-18-labeled tropomyosin receptor kinase (Trk) inhibitor for PET imaging. J Med Chem. 2018;61:1737–1743.
   PubMed Web of Science ®Google Scholar
• Bailey JJ, Schirrmacher R, Farrell K, et al. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II. Expert Opin Ther Pat. 2017;27:831–849.
   PubMed Web of Science ®Google Scholar
• Bailey JJ, Schirrmacher R, Farrell K, et al. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I. Expert Opin Ther Pat. 2017;27:733–751.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Ren X, Lu X, et al. GZD856, a novel potent PDGFRα/β inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo. Cancer Lett. 2016;375:172–178.
   PubMed Web of Science ®Google Scholar